PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-24.09%
Cash & equivalents declining -24.09% while CRVO's grows 0.51%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-24.09%
Below half of CRVO's 0.51%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.04%
Below half of CRVO's 1.31%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-17.11%
≥ 1.5x CRVO's -6.37%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-11.78%
≥ 1.5x CRVO's -5.52%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-19.98%
≥ 1.5x CRVO's -4.40%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
86.42%
Less than half of CRVO's -25.37%. David Dodd sees a more disciplined AP approach or lower volume.
-100.00%
Higher Short-Term Debt Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both CRVO and the company show zero Deferred Revenue (Current) Growth.
-55.20%
Less than half of CRVO's 23.30%. David Dodd sees fewer expansions in other current obligations.
21.67%
Less than half of CRVO's 109.54%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
21.67%
Similar yoy to CRVO's 28.32%. Walter Schloss sees parallel expansions in total liabilities.
0.96%
Less than half of CRVO's -90.00%. David Dodd sees fewer share issuances vs. competitor.
-5.35%
0.5-0.75x CRVO's -10.42%. Martin Whitman is wary of weaker retention or lower profitability.
-15.38%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-25.41%
1.25-1.5x CRVO's -18.14%. Bruce Berkowitz notes an above-average equity expansion.
-19.98%
≥ 1.5x CRVO's -4.40%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Less than half of CRVO's 341.82%. David Dodd sees less overall debt expansion vs. competitor.
23.76%
Less than half of CRVO's 75.92%. David Dodd sees better deleveraging or stronger cash buildup than competitor.